Loading
SS
Semler Scientific, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SEMLER ERIC, was filed 13 Sept 2023.
Semler Scientific, Inc.: what insiders have been doing
Semler Scientific, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 4 insiders published 6 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of Semler Scientific, Inc. for at least a year.
Compared with its exchange (5,458 companies, median 22 filings), a count of 6 filings is below the norm. Over the whole record (from 2021), the tally stands at 1 purchase and 26 sales.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
73
Thresholds
n/a
Buy Volume
€627,420
1 ops. · all time
Sell Volume
€1M
26 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$58.7M
Net incomeUS$35.2M60.0% margin
Last declaration on 16 January 2026
Declarations73 total
11,910 sharesCommon StockSEC:0001104659-26-004503:0
428,682 sharesCommon StockSEC:0001104659-26-004501:0
636,346 sharesCommon StockSEC:0001104659-26-004506:0
241,303 sharesCommon StockSEC:0001104659-26-004504:0
60,000 shares0Common StockSEC:0001104659-25-122125:0
125,000 shares@ US$2.2310.0% of flowCommon StockSEC:0001104659-25-113647:0
60,000 shares@ US$2.565.5% of flowCommon StockSEC:0001104659-25-083070:0
6,750 shares@ US$23.3214.6% of flowCommon StockSEC:0001104659-25-058670:0
3,746 shares@ US$30.48100.0% of flowCommon StockSEC:0001104659-25-058663:0
2,182 shares0Common StockSEC:0001104659-25-001743:0
1,318 shares0Common StockSEC:0001104659-25-001740:0
2,735 shares0Common StockSEC:0001104659-24-129375:0
7,875 shares@ US$23.3218.6% of flowCommon StockSEC:0001104659-24-129372:0
140,083 shares@ US$3.4419.0% of flowCommon StockSEC:0001104659-24-128026:0
1,318 shares0Common StockSEC:0001104659-24-116129:0
1,318 shares0Common StockSEC:0001104659-24-116111:0
1,318 shares0Common StockSEC:0001104659-24-116121:0
75,000 shares@ US$1.965.7% of flowCommon StockSEC:0001104659-24-116136:0
26,742 shares0Common StockSEC:0001104659-24-097769:0
780 shares@ US$28.31640.8% of flowCommon StockSEC:0001104659-24-095803:0
71,000 shares@ US$2.105.5% of flowCommon StockSEC:0001104659-24-093474:0
2,182 shares0Common StockSEC:0001104659-24-061360:0
2,182 shares0Common StockSEC:0001104659-24-061357:0
2,182 shares0Common StockSEC:0001104659-24-061359:0
25,000 shares@ US$26.9866.8% of flowCommon Stock, $0.001 par valueSEC:0000921895-23-002158:0
Canonical exit: 10 Dec 2023 (T+90)
25 of 73 declarations
About Semler Scientific, Inc.
Semler Scientific, Inc. (ticker: SMLR) is a U.S.-listed medical technology company trading on the NASDAQ in the United States. Headquartered in Campbell, California, United States, the company develops, manufactures, and markets products and services designed to support the early detection and treatment of chronic diseases, with a primary focus on cardiovascular and metabolic conditions. Its core historical asset is QuantaFlo®, a patented, FDA-cleared point-of-care test that measures arterial blood flow in the extremities and helps clinicians quickly assess the presence of peripheral arterial disease, including in asymptomatic patients. The company was co-founded in 2007 by Dr. Herbert J. Semler and has built its business around diagnostic technology intended to fit into routine clinical workflows.
From a competitive standpoint, Semler Scientific occupies a specialized niche within chronic-disease diagnostics. Rather than competing as a broad-based medtech platform, it focuses on a narrower set of solutions where speed, ease of use, and clinical utility matter. QuantaFlo is central to the company’s value proposition, and its ability to produce results in minutes supports adoption in physician offices, care networks, and other healthcare settings. The company has also introduced adjacent software and data-oriented offerings aimed at supporting disease evaluation, treatment, and practice management, although the flagship diagnostic product remains the main commercial reference point. Its operating footprint is concentrated in the United States, where it maintains its headquarters and where most of its commercial and regulatory activity is centered.
Read moreShow less
Recent developments have materially shaped the investment case. Semler Scientific has drawn attention for adopting Bitcoin as its primary treasury reserve asset, making it one of the better-known U.S. public corporate Bitcoin holders. That strategy has given the stock a distinctive profile, but it also introduces balance-sheet volatility and a more complex capital-allocation framework. In 2025, the company remained active in capital markets, including convertible debt and at-the-market financing activity. A major recent milestone was the announced merger agreement with Strive, Inc., which shareholders approved in January 2026 and which was completed shortly thereafter, signaling a significant strategic transition for the business. For investors, SMLR has therefore evolved from a single-product medtech story into a more unusual public-market case that combines healthcare diagnostics, treasury-asset strategy, and corporate restructuring on the NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
